BridgeMD
New treatment option for Community-acquired Pneumonia
Official title The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)
ClinicalTrials.gov ID: NCT06295120
What this study is testing
What is Phenoxymethylpenicillin 1.2 MIE 4 times daily?
Phenoxymethylpenicillin 1.2 MIE 4 times daily is an investigational medicine, given as an once-daily, being studied as a potential treatment for community-acquired pneumonia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this randomised controlled trial is to identify the optimal treatment duration with phenoxymethylpenicillin for community-acquired pneumonia diagnosed in general practice. Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually...
You likely can't join if
- Need for immediate hospitalisation at the time of diagnosis.
- Known allergy to beta-lactam antibiotics.
- Any coinfection necessitating antibiotic treatment.
- Use of systemic antibiotics or antivirals within the last month.
- Pre-existing lung disease (e.g., chronic obstructive pulmonary disease, bronchiectasis, asthma, lung cancer).
- Known immunosuppression (i.e., long term treatment with corticosteroid, chemotherapy, or immune disorder).
See the full eligibility criteria
- Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnoea, sputum...
- Need for immediate hospitalisation at the time of diagnosis.
- Known allergy to beta-lactam antibiotics.
- Any coinfection necessitating antibiotic treatment.
- Use of systemic antibiotics or antivirals within the last month.
- Pre-existing lung disease (e.g., chronic obstructive pulmonary disease, bronchiectasis, asthma, lung cancer).
- Known immunosuppression (i.e., long term treatment with corticosteroid, chemotherapy, or immune disorder).
- Pregnant or lactating.
- Patients not capable of consenting and/or patients deemed non-suitable for participation by the healthcare professional.
The study team makes the final eligibility decision.
Where it's taking place
- Gistrup, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gistrup, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.